Literature DB >> 21067260

Olfactomedin 4, a novel marker for the differentiation and progression of gastrointestinal cancers.

L Yu1, L Wang, S Chen.   

Abstract

Olfactomedin 4 (OLFM4) is a member of olfactomedin domain-containing protein family. Human OLFM4 is preferentially expressed in the gastrointestinal tract (stomach, small intestine and colon), prostate, and bone marrow. Recent studies demonstrate that OLFM4 is involved in the establishment and/or development of some types of malignancies, especially in gastrointestinal cancers. Induction of OLFM4 in cancer cells has a novel antiapoptotic action and promotes proliferation of cancer cells. OLFM4 regulates cell cycle and promotes S phase transition in proliferation of cancer cells. In addition, OLFM4 is associated with cancer adhesion and metastasis. In this minireview, we mainly focus on the OLFM4 expression and its biological significances in tumor differentiation and progression as well as the contributions of OLFM4 to tumorigenesis.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21067260     DOI: 10.4149/neo_2011_01_9

Source DB:  PubMed          Journal:  Neoplasma        ISSN: 0028-2685            Impact factor:   2.575


  22 in total

1.  Olfactomedin-4 Is a Candidate Marker for a Pathogenic Neutrophil Subset in Septic Shock.

Authors:  Matthew N Alder; Amy M Opoka; Patrick Lahni; David A Hildeman; Hector R Wong
Journal:  Crit Care Med       Date:  2017-04       Impact factor: 7.598

2.  Olfactomedin 4 suppresses tumor growth and metastasis of mouse melanoma cells through downregulation of integrin and MMP genes.

Authors:  Key Sun Park; Kee Kwang Kim; Zheng-Hao Piao; Mi Kyung Kim; Hyun Jean Lee; Yong Chan Kim; Ki Sung Lee; Jeung-Hoon Lee; Kyoon Eon Kim
Journal:  Mol Cells       Date:  2012-11-15       Impact factor: 5.034

3.  Amyloid fibril formation by the glaucoma-associated olfactomedin domain of myocilin.

Authors:  Susan D Orwig; Christopher W Perry; Laura Y Kim; Katherine C Turnage; Rong Zhang; Douglas Vollrath; Ingeborg Schmidt-Krey; Raquel L Lieberman
Journal:  J Mol Biol       Date:  2011-12-13       Impact factor: 5.469

Review 4.  Sepsis Biomarkers.

Authors:  Hector R Wong
Journal:  J Pediatr Intensive Care       Date:  2019-01-11

5.  Differential Transcriptomic Profiles Following Stimulation with Lipopolysaccharide in Intestinal Organoids from Dogs with Inflammatory Bowel Disease and Intestinal Mast Cell Tumor.

Authors:  Dipak Kumar Sahoo; Dana C Borcherding; Lawrance Chandra; Albert E Jergens; Todd Atherly; Agnes Bourgois-Mochel; N Matthew Ellinwood; Elizabeth Snella; Andrew J Severin; Martin Martin; Karin Allenspach; Jonathan P Mochel
Journal:  Cancers (Basel)       Date:  2022-07-20       Impact factor: 6.575

6.  The glaucoma-associated olfactomedin domain of myocilin is a novel calcium binding protein.

Authors:  Rebecca K Donegan; Shannon E Hill; Katherine C Turnage; Susan D Orwig; Raquel L Lieberman
Journal:  J Biol Chem       Date:  2012-11-05       Impact factor: 5.157

7.  State of the human proteome in 2013 as viewed through PeptideAtlas: comparing the kidney, urine, and plasma proteomes for the biology- and disease-driven Human Proteome Project.

Authors:  Terry Farrah; Eric W Deutsch; Gilbert S Omenn; Zhi Sun; Julian D Watts; Tadashi Yamamoto; David Shteynberg; Micheleen M Harris; Robert L Moritz
Journal:  J Proteome Res       Date:  2013-12-06       Impact factor: 4.466

8.  Plasma olfactomedin 4 level in peripheral blood and its association with clinical features of breast cancer.

Authors:  Chaoqian Liu; Yan Guo; Weiwei Wu; Zhenzhen Zhang; Lu Xu; Kainan Wu; Wei Hu; Guoping Liu; Junyi Shi; Cheng Xu; Jianwei Bi; Yuan Sheng
Journal:  Oncol Lett       Date:  2017-10-16       Impact factor: 2.967

9.  Ligands for glaucoma-associated myocilin discovered by a generic binding assay.

Authors:  Susan D Orwig; Pamela V Chi; Yuhong Du; Shannon E Hill; Marchello A Cavitt; Amrithaa Suntharalingam; Katherine C Turnage; Chad A Dickey; Stefan France; Haian Fu; Raquel L Lieberman
Journal:  ACS Chem Biol       Date:  2013-12-09       Impact factor: 5.100

10.  Molecular profiling of peripheral blood is associated with circulating tumor cells content and poor survival in metastatic castration-resistant prostate cancer.

Authors:  Mercedes Marín-Aguilera; Òscar Reig; Juan José Lozano; Natalia Jiménez; Susana García-Recio; Nadina Erill; Lydia Gaba; Andrea Tagliapietra; Vanesa Ortega; Gemma Carrera; Anna Colomer; Pedro Gascón; Begoña Mellado
Journal:  Oncotarget       Date:  2015-04-30
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.